首页> Multiple sclerosis (Houndmills, Basingstoke, England)> Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

导出 OA

翻译打印收藏纠错

第一作者： Sibyl,Wray

第一单位： Hope Neurology MS Center, Knoxville, TN, USA.

作者： Sibyl,Wray ^[1] ; Eva,Havrdova ^[2] ; David R,Snydman ^[3] ; Douglas L,Arnold ^[4] ; Jeffrey A,Cohen ^[5] ; Alasdair J,Coles ^[6] ; Hans-Peter,Hartung ^[7] ; Krzysztof W,Selmaj ^[8] ; Howard L,Weiner ^[9] ; Nadia,Daizadeh ^[10] ; David H,Margolin ^[10] ; Madalina C,Chirieac ^[10] ; D Alastair S,Compston ^[6]

作者单位： Hope Neurology MS Center, Knoxville, TN, USA. ^[1] MS Center, Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic. ^[2] Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA. ^[3] Montréal Neurological Institute, McGill University, Montréal, QC, Canada. ^[4] Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. ^[5] University of Cambridge School of Clinical Medicine, Cambridge, UK. ^[6] Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. ^[7] Medical University of Łódź, Łódź, Poland. ^[8] The Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA. ^[9] Sanofi, Cambridge, MA, USA. ^[10]

关键词 Alemtuzumab disease-modifying therapy infection relapsing-remitting multiple sclerosis safety